

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED  
SECRETARY OF THE SENATE  
01 FEB 14 PM 2:22

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <b>Amgen Inc.</b>			
2. Address <small>Check if different than previously reported</small> <b>1300 Eye Street, NW; Suite 270W</b>			
3. Principal Place of Business (if different from line 2)			
City: <b>Washington</b>		State/Zip (or Country): <b>DC 20005</b>	
4. Contact Name <b>L. Nicole Antorcha</b>	Telephone <b>202/289-8212</b>	E-mail (optional) <b>nickiea@amgen.com</b>	5. Senate ID # <b>3867-12</b>
7. Client Name <b>Self</b>			6. House ID # <b>31560000</b>

**TYPE OF REPORT** 8. Year  Midyear (January 1-June 30) OR  Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report   
 10. Check if this is a Termination Report. Termination Date \_\_\_\_\_ 11. No lobbying Activity

<b>INCOME OR EXPENSES - Complete Either Line 12 OR Line 13</b>	
<p align="center"><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 _____          \$10,000 or more <input type="checkbox"/> \$ _____  <small>(Income In excess of \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 _____          \$10,000 or more <input checked="" type="checkbox"/> \$ <u>1,560,000</u>  <small>(Expenses in excess of \$20,000)</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only  <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature *Peter B. Teeley* Date 2/14/01  
 Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 4149: To amend Title XVIII of the Social Security Act to preserve coverage of drugs and biologicals under Part B of the Medicare Program

H.R. 4680: To amend title XVIII of the Social Security Act to provide for a voluntary program for prescription drug coverage under the Medicare Program, to modernize the Medicare Program, and for other purposes.

H. 3983: Helping to Improve Technology Education and Achievement Act of 2000

S. 2957: To amend Title XVIII of the Social Security Act to preserve coverage of drugs and biologicals under Part B of the Medicare Program

S. 2807: Medicare Prescription Drug and Modernization Act of 2000

S. 2520: Medicine Equity and Drug Safety Act of 2000

S. 2045: American Competitiveness in the Twenty-First Century Act

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Peter B. Teeley		
Rita E. Norton		
L. Nicole Antorcha		X

19. Interest of each foreign entity in the specific issues listed on line 16 above.  Check if None

Signature *Peter Teeley* Date 2/14/01

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit; Medicare Reimbursement

**H.R. 4149:** To amend Title XVIII of the Social Security Act to preserve coverage of drugs and biologicals under Part B of the Medicare Program

**H.R. 4680:** To amend title XVIII of the Social Security Act to provide for a voluntary program for prescription drug coverage under the Medicare Program, to modernize the Medicare Program, and for other purposes.

**S. 2957:** To amend Title XVIII of the Social Security Act to preserve coverage of drugs and biologicals under Part B of the Medicare Program

**S. 2807:** Medicare Prescription Drug and Modernization Act of 2000

**S. 2520:** Medicine Equity and Drug Safety Act of 2000


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
Executive Office of the President  
Health Care Financing Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Peter B. Teeley		
Rita E. Norton		
Judi A. Teske		
L. Nicole Antorcha		X

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 2/14/01

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Medical Incentives Tax Credit (no bill numbers apply)

Research and Development Tax Credit (no bill numbers apply)


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Peter B. Teeley		
Rita E. Norton		

19. Interest of each foreign entity in the specific issues listed on line 16 above.  Check if None

Signature  Date 2/14/01

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

S. 2553, H.R. 4572: Departments of Labor, Health & Human Services, and Education and Related Agencies Appropriations Act, 2001

S. 2536, HR 4461: Departments of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001

S. 2521, HR 4425: Military Construction Appropriations Act, 2001

HR 4942: Departments of Commerce, Justice State and Judiciary Appropriations, 2001

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Peter B. Teeley		
Rita E. Norton		
L. Nicole Antorcha		X

19. Interest of each foreign entity in the specific issues listed on line 16 above.  Check if None

Signature *Peter Teeley* Date 2/14/01

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations

Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

**16. Specific lobbying issues**

Patent Issues Relevant to Hatch-Waxman Reform


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Peter B. Teeley		
Rita E. Norton		
L. Nicole Antorcha		X

19. Interest of each foreign entity in the specific issues listed on line 16 above.  Check if None

Signature  Date 2/14/01

Printed Name and Title Peter B. Teeley, Senior Vice President of Government Relations